{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 25,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/15",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.415
      },
      "kind": "list",
      "text": "Differentiated Features: Highly selective - Lack of immunosuppression; Unique mechanism of action - Complete shut-down of the SRC pathway by scaffold and catalytic domain inactivation; Ability to cross the blood-brain-barrier",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "062f0dec-0b2d-4ba8-9706-59c5df845c55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.238
      },
      "kind": "list",
      "text": "Precision Medicine Approach: Discovered at the University of Edinburgh, Scotland; A potent, novel, small molecule inhibitor of YES1/SRC signaling; YES1-Hippo pathway alteration associated with sensitivity to NXP900 in squamous cell models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09a3ce98-cfde-42ad-a33c-e5657bbce139",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.769
      },
      "kind": "list",
      "text": "Phase 1 Program: Phase 1a dose escalation clinical trial initiated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8af6ee8e-c9fc-42fc-bc5a-92968eca096c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.592
      },
      "kind": "list",
      "text": "Strong Preclinical Proof of Concept: POC in multiple xenograft models – significant single-agent activity in squamous cell cancer models; Ability to re-sensitize resistant NSCLC cells to osimertinib (2022 paper); Ability to reverse resistance to enzalutamide in mCRPC (2023 paper)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1200b69-c29c-440c-9431-0159ddcd5295",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.43,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "NXP900 Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b07ac11-8bbf-4cf6-bff5-0061ab52f7fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7cb57e07-601d-4aef-b6b6-56541ebacd22",
      "evidence": "The document presents NXP800 and NXP900 as potential solutions, with early-stage results and market opportunity.",
      "position": 1,
      "objective": "Can Nuvectis Pharma deliver quick wins and big bets in the cancer treatment market?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}